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Too Restrictive
Exclusion Criteria in
Advanced Stage Lung
Cancer Therapeutic
Trials: Are We Missing
the Target?
To the Editor:
With 965,000 new cases worldwide
in 2002 in men and 387,000 new cases in
women, lung cancer is the most common
cancer. Because of its poor prognosis,
1.2  106 people died of lung cancer in
that year.1 Though its incidence has
stopped increasing, particularly for men,
in countries where efficient tobacco con-
trol policies have been implemented, its
global incidence is still on the rise.1
This dramatic situation is due to
the high worldwide prevalence of tobacco
smoking and the fact that most diagnoses
are made at advanced stages when only
palliative treatments (chemotherapy ra-
diotherapy) can be prescribed, surgery be-
ing the only curative treatment.1
Obviously, curbing the tobacco
pandemic would be an efficient way to
prevent lung cancer, but worldwide to-
bacco smoking is still on the rise, due
to the tobacco industry’s highly efficient
marketing and promotion efforts. Further-
more, even if tobacco smoking were to
totally vanish, the lung cancer pandemic
would last for a long time since at present,
at least in developed countries, nearly one
in 2 lung cancers are diagnosed in patients
who had already given up smoking.2
An efficient early detection proce-
dure has yet to be described for this
cancer,3 therefore, to improve lung can-
cer prognosis, it is important to try to
improve treatment (chemotherapy  ra-
diotherapy) efficacy. This can only be
done through the development of more
efficient treatments with the enrollment
of patients in clinical trials.
Unfortunately, there are currently
very few patients with advanced stage
lung cancer (less than 5%) enrolled in
clinical trials.4 For example, in our depart-
ment, a prospective study of inclusion/
noninclusion in clinical trials of patients
admitted for stages IIIB and IV nonsmall
cell lung cancer (NSCLC) in 2007 showed
that, among 217 patients admitted for lung
cancer, according to TNM staging, 123
patients with NSCLC (m/f ratio: 96/27;
mean age: 61  12 years; 64 adenocarci-
noma, 32 squamous cell carcinomas, 2
neuroendocrine carcinomas, 2 large cell
carcinomas, 17 undifferentiated carcino-
mas, and 6 without histology) could have
been enrolled in clinical trials open at time
of admission. However, only 12 patients
(10%) were actually included in a trial.
The exclusion criteria were as follows: 
symptomatic brain metastases (n  29),
common comorbidities (Charlson Comor-
bidity Index-CCI- 3) (n  28), WHO
PS 2 and/or life expectancy3 months
(n  23), patient refusal or specified re-
quirements (n  13), technical limitation
(tumor biopsy size too small for further
molecular analysis, n  9), patient trans-
ferred to another institution (n  7), lack
of organization (n  2).
Obviously, such a low percentage
of included patients is not a representa-
tive sample of patients with advanced
NSCLC. Low accrual rates have been
observed in other clinical settings and
several parameters have been suggested
to be responsible: age, ethnicity, insur-
ance status, presence of an oncology
specialist, etc.4,5 In the present study,
these parameters were not involved
since all patients could have been in-
cluded in clinical trials according to
their age, clinical status, TNM staging,
acceptance, etc. Our patients were
mainly not included because of overly
restrictive clinical trial exclusion crite-
ria. As a result, one might question
whether the observations resulting from
therapeutic protocols based on such re-
strictive criteria, inevitably leading to bi-
ased samples of patients, should be ap-
plied to all patients. Thus, it is suggested
that, instead of studying a very exclusive
subset of patients, future protocols should
be targeted toward the main patient pop-
ulation, regardless of clinical status, but
for terminally ill patients.
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Zoledronic Acid and
Survival in Patients
with Metastatic Bone
Disease From Lung
Cancer and Elevated
Markers of Osteoclast
Activity: A Novel
Molecular Mechanism
To the Editor:
Dear Sir, I read with great interest
the paper by Hirsh et al.1
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This work shows that zoledronic
markedly reduced skeletal-related events
in men with advanced lung cancer and
bone metastases compared with a pla-
cebo. I would like to complete the dis-
cussion of Hirsh et al.1 by introducing a
major route through which zoledronic
could reduce skeletal complications in
patients with bone metastases.
In metastatic lung cancer, the mes-
enchymal stromal cells are the neoplas-
tic cells and induce recruitment and for-
mation of osteoclasts. The osteoclastic
cells, which cause bony destruction, are
thought to be recruited from normal
monocytic preosteoclasts by stromal cell
expression of the ligand for receptor acti-
vator of nuclear factor kappaB (RANKL).
RANKL is an osteoclastogenesis factor
released by osteoblasts, stromal cells,
and activated T cells. RANK is a re-
ceptor that is present on the cell mem-
brane of osteoclasts, monocytes, and os-
teoblasts. Studies have shown the role of
RANKL in metastatic lung cancer as
evidenced by the inhibitory effect of
osteoprotegerin (a decoy receptor of
RANKL) on RANKL-mediated tu-
moral osteoclastogenesis.2–4
Fusion of the cell membrane of
mononuclear preosteoclasts is a critical
initial step in osteoclast maturation.
Cholesterol in the membranes of mono-
cytes is involved in the osteoclast-like
cell formation by means of cellular mem-
brane fusion events. Addition of native
LDL cholesterol increases osteoclast via-
bility by suppressing spontaneous apopto-
sis, while cholesterol removal strongly in-
duces apoptosis in osteoclast. Moreover,
cholesterol removal by HDL, apolipopro-
tein A1 (ApoA1) or methyl--cyclodex-
trin triggers induction of apoptosis and
osteoclast death. Cholesterol in the cell
membrane is derived from de novo syn-
thesis through HMG-CoA reductase.5,6
Zoledronic act on bone metabo-
lism by binding and blocking the en-
zyme farnesyl diphosphate synthase in
the HMG-CoA reductase pathway. Al-
though inhibition of protein prenylation
may affect many proteins found in an
osteoclast, disruption to the lipid modi-
fication of Ras, Rho, Rac proteins has
been speculated to underlie the effects of
zoledronic. These proteins can affect os-
teoclastogenesis, cell survival, and cy-
toskeletal dynamics. In particular, the
cytoskeleton is vital for maintaining the
“ruffled border” that is required for con-
tact between a resorbing osteoclast and a
bone surface.7,8 Also, data obtained in
recent studies have demonstrated that
zoledronic stimulate the osteoprotegrin
production by osteoblasts which can
lead to a significant reduction in
RANKL.9,10
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